Cargando…

Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis

INTRODUCTION: Although the treatment paradigm for hepatocellular carcinoma (HCC) has recently shifted in favour of checkpoint inhibitor (CPI)-based treatment options, the tyrosine kinase inhibitors (TKI) currently approved for the treatment of HCC are expected to remain the cornerstone of HCC treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sagmeister, Paula, Daza, Jimmy, Ofner, Andrea, Ziesch, Andreas, Ye, Liangtao, Ben Khaled, Najib, Ebert, Matthias, Mayerle, Julia, Teufel, Andreas, De Toni, Enrico N, Munker, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278726/ https://www.ncbi.nlm.nih.gov/pubmed/35845819 http://dx.doi.org/10.2147/JHC.S356333

Ejemplares similares

Prognostic Significance and Functional Relevance of Olfactomedin 4 in Early-Stage Hepatocellular Carcinoma
por: Ye, Liangtao, et al.
Publicado: (2020)

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
por: Ye, Liangtao, et al.
Publicado: (2019)

p70 Ribosomal Protein S6 Kinase Is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in Mice
por: Reiter, Florian P., et al.
Publicado: (2021)

Deep View of HCC Gene Expression Signatures and Their Comparison with Other Cancers
por: Qian, Yuquan, et al.
Publicado: (2022)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
por: Sun, Tao, et al.
Publicado: (2023)

TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status
por: Ben Khaled, Najib, et al.
Publicado: (2022)

Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
por: Roessler, Daniel, et al.
Publicado: (2022)

Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review
por: Reiter, Florian P., et al.
Publicado: (2022)

Letter to the editor: vaccination against upper respiratory infections is a matter of survival in alcoholic liver disease
por: Itzel, Timo, et al.
Publicado: (2023)

GLP2-GLP2R signal affects the viability and EGFR-TKIs sensitivity of PC9 and HCC827 cells
por: Song, Bin, et al.
Publicado: (2022)

Prognostic Cancer Gene Expression Signatures: Current Status and Challenges
por: Qian, Yuquan, et al.
Publicado: (2021)

TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs
por: Yang, Chong, et al.
Publicado: (2023)

Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival
por: Brunner, Stefan M., et al.
Publicado: (2017)

Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study
por: De Toni, Enrico N, et al.
Publicado: (2020)

Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis
por: Guo, Yang, et al.
Publicado: (2015)

Hepamine - A Liver Disease Microarray Database, Visualization Platform and Data-Mining Resource
por: Itzel, Timo, et al.
Publicado: (2020)

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
por: Seidensticker, Max, et al.
Publicado: (2023)

Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptormediated apoptosis
por: De Toni, Enrico N., et al.
Publicado: (2016)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers
por: Hocke, Sandra, et al.
Publicado: (2016)

Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab
por: Leipe, Jan, et al.
Publicado: (2020)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
por: Yan, Han, et al.
Publicado: (2015)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC
por: Becker, Diana, et al.
Publicado: (2012)

Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis
por: Alunni-Fabbroni, Marianna, et al.
Publicado: (2021)

Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice
por: Feng, T, et al.
Publicado: (2017)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma
por: Li, Qiwen, et al.
Publicado: (2021)

Genetic targeting of B-Raf(V600E) affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells
por: Hirschi, Benjamin, et al.
Publicado: (2014)

HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011)

Novel agents and strategies for overcoming EGFR TKIs resistance
por: Niu, Fei-Yu, et al.
Publicado: (2014)

Adjuvant EGFR-TKIs-based therapy: are we ready?
por: Tam, Terence
Publicado: (2020)

Circulating miR-21 as a prognostic biomarker in HCC treated by CT-guided high-dose rate brachytherapy
por: Stechele, Matthias, et al.
Publicado: (2023)

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
por: Koulouris, Andreas, et al.
Publicado: (2022)

Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis
por: Zheng, Hong, et al.
Publicado: (2017)

Response to Chen et al.
por: Ye, Liangtao, et al.
Publicado: (2020)

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
por: Chen, Yanxin, et al.
Publicado: (2019)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
por: Milovancev, Aleksandar, et al.
Publicado: (2015)

Are TKIs favourable for the elderly with non-small-cell lung cancer?
por: Rossi, Sabrina, et al.
Publicado: (2016)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ojkopravhashdmds05covtiisu